TCT: PLATO Subset Analysis Confirms Ticagrelor Superiority (CME/CE)
Submitted by MedicalReplies on Thursday, 24 September 2009No Comment
SAN FRANCISCO (MedPage Today) — Drilling down into data from a head-to-head trial of ticagrelor (Brilinta) and clopidogrel (Plavix) revealed that the investigational agent did a better job of reducing strokes, heart attacks, and cardiovascular deaths.
Original post:
TCT: PLATO Subset Analysis Confirms Ticagrelor Superiority (CME/CE)
Leave your response!